摘要
目的研究利培酮联合丙戊酸钠用于躁狂发作急性期治疗的安全性和有效性。方法 97例躁狂发作急性期患者作为研究对象,随机分为试验组(49例)和对照组(48例)。试验组采用丙戊酸钠联合利培酮治疗,对照组采用丙戊酸钠治疗,观察6周,通过Bech-Rafaelsen躁狂量表(BRMS)评价有效性,并观察用药安全性。结果两组患者均顺利治疗,无一例脱落。治疗后6周,试验组临床治疗总有效率为87.8%,与对照组的85.4%比较,差异无统计学意义(P>0.05)。治疗前两组BRMS评分比较差异无统计学意义(P>0.05)。两组治疗后1、2、4、6周末BRMS评分均逐渐降低,均低于治疗前(P<0.05)。研究组治疗后1、2、4周末BRMS评分低于对照组,差异有统计学意义(P<0.05);两组治疗后6周末BRMS评分比较差异无统计学意义(P>0.05)。两组患者不良反应主要为轻度和中度,可耐受,经过相应处理后不良反应缓解,试验组不良反应发生率为24.5%,与对照组的22.9%比较,差异无统计学意义(P>0.05)。结论治疗急性躁狂症患者应用利培酮联合丙戊酸钠,能够缩短起效时间,安全有效。
Objective To research safety and effectiveness by risperidone combined with sodium valproate in the treatment of acute period of manic episode. Methods A total of 97 patients with acute period of manic episode as study subjects were randomly divided into experimental group（49 cases） and control group（48 cases）. The experimental group received risperidone combined with sodium valproate for treatment, and the control group received sodium valproate for treatment. After 6-week observation, Bech-Rafaelsen mania rating scale（BRMS） was used to evaluate effectiness in patients, and their medication safety was observed. Results Both groups received successful treatment, without any fall-off case. In 6 weeks after treatment, the experimental group had total effective rate in clinical treatment as 87.8%, which was 85.4% in the control group, and their difference had no statistical significance（P〉0.05）. There was no statistically significant difference of BRMS score between the two group before treatment（P〉0.05）. At the end of 1, 2, 4, 6 weeks in treatment, both groups had gradually lower BRMS scores than those before treatment（P〈0.05）. The experimental group had all lower BRMS score at the end of 1, 2, 4 weeks in treatment than the control group, and the difference had statistical significance（P〈0.05）. The difference of BRMS score at the end of 6 weeks in treatment between the two groups had no statistical significance（P〉0.05）. Both groups showed tolerable mild and moderate adverse reactions, which were relieved after corresponding treatment. The experimental group had incidence of adverse reactions as 24.5%, which was 22.9% in the control group, ad their difference had no statistical significance（P〉0.05）. Conclusion Implement of risperidone combined with sodium valproate in the treatment of acute period of manic episode can shorten onset time, with safety and effectives.
出处
《中国实用医药》
2017年第16期46-48,共3页
China Practical Medicine
关键词
躁狂发作
利培酮
疗效
安全性
Manic episode
Risperidone
Curative effect
Safety
